Insider filing · ATTO

Goldman Sachs Group Inc bought $10.3M of Attovia Therapeutics (ATTO)

Executed Aug 5, disclosed Aug 14, 8 days later, against a two-business-day limit.

Over the 21 trading sessions from the disclosed entry session (Aug 13), the stock returned +26.2% (delay-adjusted); from the execution session (Aug 5), +10.1%. Derived: entry at the session's open, exit at the close 20 sessions later.

GI Goldman Sachs Group Inc Other profile →

Goldman Sachs Group Inc (Other) filed 3 Form 4 reports as a reporting entity in the trailing twelve months (3 purchases, 2 sales, 2 filed past the two-business-day deadline), most often in Attovia Therapeutics, Inc. Common Stock (ATTO). Across 2 priced purchase filings, the average 21-session return was +14.3% from execution and +23.1% from disclosure (delay-adjusted; derived). The largest single filing was $10.3M of ATTO (585,000 sh across 2 lots, as filed), executed Aug 5.

ATTO Attovia Therapeutics, Inc. Common Stock ATTO · 8 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→